Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;13(4):431–439. doi: 10.1111/j.1750-3639.2003.tb00474.x

Frequent LOH at Chromosome 12q22‐23 and Apaf‐1 Inactivation in Glioblastoma

Takuya Watanabe 1, Yuichi Hirota 1, Yasuaki Arakawa 1, Hironori Fujisawa 1, Osamu Tachibana 1, Mitsuhiro Hasegawa 1, Junkoh Yamashita 1, Yutaka Hayashi 1,✉
PMCID: PMC8095738  PMID: 14655749

Abstract

Glioblastoma (GB) often has loss of heterozygosity on the chromosomes, 1p, 10p, 10q, 11p, 17p, 19q, 22q, and several others. In the case of chromosome 12q; however, it remains to be seen whether LOH occurs. Apaf‐1, the apoptotic protease activating factor‐1, located at chromosome 12q22‐23, is a major effecter of the p53 mediated apoptosis pathway, and Apaf‐1 inactivation due to chromosome 12q22‐23 LOH and hypermethylation may be involved in some of the neoplasms in malignancy. However, little is known about the frequency of the 12q22‐23 LOH or the state of Apaf‐1 in GB. To elucidate their involvement in GB, we analyzed a series of 33 GBs for chromosome 12q22‐23 LOH, Apaf‐1 mRNA expression, and Apaf‐1 protein expression, using microsatellite analysis, reverse transcription (RT) ‐PCR analysis, and immunohistochemical (IHC) analysis, respectively. We also evaluated if and how the 12q22‐23 LOH correlated with the p53 gene mutation and EGFR gene amplification. Chromosome 12q22‐23 LOH was detected in 14 (42%) of 33 cases. Among the examined cases with LOH at 12q22‐23, a low expression of Apaf‐1 mRNA was detected in 9 (69%) of 13 cases, and a low expression of Apaf‐1 protein was detected in 12 (86%) of 14 cases. The 12q22‐23 LOH was significantly correlated with low expression of mRNA and protein (p<0.05, p<0.001 respectively). The p53 gene mutation and EGFR gene amplification were found in 13 cases (39%) and 8 cases (24%), respectively, and these gene alterations were inversely correlated. However, 12q22‐23 LOH had no correlations with the p53 gene mutation or EGFR gene amplification. Six of 9 GBs (67%) with neither p53 gene mutation nor EGFR gene amplification tested positive for 12q22‐23 LOH. These GBs are likely to belong to another subset independent from the 2 common genetic subsets in GB (one with p53 gene mutation and without EGFR gene amplification, and the other with EGFR gene amplification and without p53 gene mutation). Twenty‐three (70%) out of the 33 GBs with the 12q22‐23 LOH also tested positive for Apaf‐1 inactivation or p53 gene mutation. This high frequency of alterations in the apoptosis‐associated factors prompts a speculation that abrogation of the Apaf‐1 and p53 mediated apoptosis pathway may play an important role in the tumorigenesis of GB.

Full Text

The Full Text of this article is available as a PDF (277.1 KB).

References

  • 1. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, Rowitch DH, Louis DN, DePinho RA (2002) Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269–277. [DOI] [PubMed] [Google Scholar]
  • 2. Bala S, Oliver H, Renault B, Montgomery K, Dutta S, Rao P, Houldsworth J, Kucherlapati R, Wang X, Chaganti RS, Murty VV (2000) Genetic analysis of the APAF1 gene in male germ cell tumors. Genes Chromosomes Cancer 28:258–268. [DOI] [PubMed] [Google Scholar]
  • 3. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10:687–692. [DOI] [PubMed] [Google Scholar]
  • 4. Cecconi F, Gruss P (2001) Apaf1 in developmental apoptosis and cancer: how many ways to die Cell Mol Life Sci 58:1688–1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Costello JF, Berger MS, Huang HS, Cavenee WK (1996) Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56:2405–2410. [PubMed] [Google Scholar]
  • 6. Deen DF, Chiarodo A, Grimm EA, Fike JR, Israel MA, Kun LE, Levin VA, Marton LJ, Packer RJ, Pegg AE, et al., 0167‐594x, Congresses (1993) Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute. J Neurooncol 16:243–272. [DOI] [PubMed] [Google Scholar]
  • 7. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21:5400–5413. [DOI] [PubMed] [Google Scholar]
  • 8. Esteller M, Herman JG (2002) Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196:1–7. [DOI] [PubMed] [Google Scholar]
  • 9. Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, Jia L (2003) Role of DNA methylation in the suppression of Apaf‐1 protein in human leukaemia. Oncogene 22:451–455. [DOI] [PubMed] [Google Scholar]
  • 10. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 80:65–72. [DOI] [PubMed] [Google Scholar]
  • 11. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG (2000) p53 gene mutation and ink4a‐arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19:3816–3822. [DOI] [PubMed] [Google Scholar]
  • 12. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG (2002) DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 111:115–127. [DOI] [PubMed] [Google Scholar]
  • 13. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O'Connor T, Ward R (2002) CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122:1376–1387. [DOI] [PubMed] [Google Scholar]
  • 14. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7:871–875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Hegi ME, Zur Hausen A, Ruedi D, Malin G, Kleihues P (1997) Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer 73:57–63. [DOI] [PubMed] [Google Scholar]
  • 16. Holland EC, Hively WP, DePinho RA, Varmus HE (1998) A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell‐cycle arrest pathways to induce glioma‐like lesions in mice. Genes Dev 12:3675–3685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Iwato M, Tachibana O, Tohma Y, Nitta H, Hayashi Y, Yamashita J (2000) Molecular analysis for p53 and mdm2 in intracranial germ cell tumors. Acta Neuropathol (Berl) 99:21–25. [DOI] [PubMed] [Google Scholar]
  • 18. Jia L, Srinivasula SM, Liu FT, Newland AC, Fernandes‐Alnemri T, Alnemri ES, Kelsey SM (2001) Apaf‐1 protein deficiency confers resistance to cytochrome c‐dependent apoptosis in human leukemic cells. Blood 98:414–421. [DOI] [PubMed] [Google Scholar]
  • 19. Jones PA (2001) Cancer. Death and methylation. Nature 409:141, 143–144. [DOI] [PubMed] [Google Scholar]
  • 20. Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013–2026. [DOI] [PubMed] [Google Scholar]
  • 21. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H (2000) Glioblastoma In: Pathology and Genetics. Tumours of the Nervous System 2nd. Kleihues P, Cavenee WK (eds.), Chapter 1, pp. 29–39, IARC Press, Lyon . [Google Scholar]
  • 22. Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, Feuerstein BG (2001) Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61:7683–7688. [PubMed] [Google Scholar]
  • 23. Louis DN (1997) A molecular genetic model of astrocytoma histopathology. Brain Pathol 7:755–764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Louis DN, Gusella JF (1995) A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 11:412–415. [DOI] [PubMed] [Google Scholar]
  • 25. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15:1311–1333. [DOI] [PubMed] [Google Scholar]
  • 26. Muller MB, Schmidt MC, Schmidt O, Hayashi Y, Rollbrocker B, Waha A, Fimmers R, Volk B, Warnke P, Ostertag CB, Wiestler OD, von Deimling A (1999) Molecular genetic analysis as a tool for evaluating stereotactic biopsies of glioma specimens. J Neuropathol Exp Neurol 58:40–45. [DOI] [PubMed] [Google Scholar]
  • 27. Murty VV, Montgomery K, Dutta S, Bala S, Renault B, Bosl GJ, Kucherlapati R, Chaganti RS (1999) A 3‐Mb high‐resolution BAC/PAC contig of 12q22 encompassing the 830‐kb consensus minimal deletion in male germ cell tumors. Genome Res 9:662–671. [PMC free article] [PubMed] [Google Scholar]
  • 28. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, Kleihues P, Ohgaki H (2001) p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11:159–168. 438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN (1996) Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki‐67 proliferation indices. J Neuropathol Exp Neurol 55:1026–1031. [PubMed] [Google Scholar]
  • 30. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324–1330. [PubMed] [Google Scholar]
  • 31. Robles AI, Bemmels NA, Foraker AB, Harris CC (2001) APAF‐1 is a transcriptional target of p53 in DNA damage‐induced apoptosis. Cancer Res 61:6660–6664. [PubMed] [Google Scholar]
  • 32. Rollbrocker B, Waha A, Louis DN, Wiestler OD, von Deimling A (1996) Amplification of the cyclin‐dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol (Berl) 92:70–74. [DOI] [PubMed] [Google Scholar]
  • 33. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer‐Puttlitz B, Wiestler OD, Louis DN, Fimmers R, von Deimling A (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321–328. [DOI] [PubMed] [Google Scholar]
  • 34. Shinoura N, Sakurai S, Shibasaki F, Asai A, Kirino T, Hamada H (2002) Co‐transduction of Apaf‐1 and cas‐pase‐9 highly enhances p53‐mediated apoptosis in gliomas. Br J Cancer 86:587–595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS, Lothe RA (2001) Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet 127:64–70. [DOI] [PubMed] [Google Scholar]
  • 36. Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW (1999) Apaf‐1 and cas‐pase‐9 in p53‐dependent apoptosis and tumor inhibition. Science 284:156–159. [DOI] [PubMed] [Google Scholar]
  • 37. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz‐Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon‐Cardo C, Lowe SW (2001) Inacti‐vation of the apoptosis effector Apaf‐1 in malignant melanoma. Nature 409:207–211. [DOI] [PubMed] [Google Scholar]
  • 38. Steinbach JP, Supra P, Huang HJ, Cavenee WK, Weller M (2002) CD95‐mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathol 12:12–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, New‐comb EW (2000) Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 10:249–259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O, Kleihues P, Ohgaki H (1998) Necrogenesis and Fas/APO‐1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 57:239–245. [DOI] [PubMed] [Google Scholar]
  • 41. Tong CY, Zheng PP, Pang JC, Poon WS, Chang AR, Ng HK (2001) Identification of novel regions of allelic loss in ependymomas by high‐resolution allelotyping with 384 microsatellite markers. J Neurosurg 95:9–14. [DOI] [PubMed] [Google Scholar]
  • 42. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150–153. [PubMed] [Google Scholar]
  • 43. von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopmann J, Maintz D et al (2000) Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59:544–558. [DOI] [PubMed] [Google Scholar]
  • 44. von Deimling A, Louis DN, Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15:328–338. [DOI] [PubMed] [Google Scholar]
  • 45. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN, 1015–6305, Article J (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3:19–26. [DOI] [PubMed] [Google Scholar]
  • 46. Waha A, Rollbrocker B, Wiestler OD, von Deimling A (1996) A polymerase chain reaction‐based assay for the rapid detection of gene amplification in human tumors. Diagn Mol Pathol 5:147–150. [DOI] [PubMed] [Google Scholar]
  • 47. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H, 1015–6305, Article J (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217–223; discussion 223–214. [DOI] [PubMed] [Google Scholar]
  • 48. Wooten EC, Fults D, Duggirala R, Williams K, Kyritsis AP, Bondy ML, Levin VA, O'Connell P (1999) A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution. Neuro-oncol 1:169–176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Zornig M, Hueber A, Baum W, Evan G (2001) Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551:F1–37. [DOI] [PubMed] [Google Scholar]
  • 50. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X (1997) Apaf‐1, a human protein homologous to C. elegans CED‐4, participates in cytochrome c‐dependent activation of cas‐pase‐3. Cell 90:405–413. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES